Non-astrocytic gliomas

Published on 20/03/2015 by admin

Filed under Pathology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 5 (1 votes)

This article have been viewed 2807 times

36

Non-astrocytic gliomas

The following glial neoplasms are considered in this chapter: oligodendrogliomas, ependymomas, and mixed gliomas.

OLIGODENDROGLIOMAS

Oligodendrogliomas usually present in adulthood. They show a broad range of behaviors; some neoplasms with bland cytologic features grow extremely slowly and are associated with a long history of epilepsy, yet anaplastic oligodendrogliomas can have a poor prognosis (Table 36.1). Attempts to categorize this heterogeneity in a variety of grading systems have been successful in separating groups of patients with distinct outcomes, but consensus supports the view that two broad categories are sufficient. These correspond to ‘oligodendroglioma’ and ‘anaplastic oligodendroglioma’, grade 2 and grade 3, respectively in the WHO classification.

Table 36.1

Prognostic indicators in oligodendrogliomas

Age (young age – favorable)

Postoperative Karnofsky score (high score – favorable)

Pathologic distinction between WHO grade 2 and WHO grade 3 (anaplastic) neoplasms (WHO grade 2 – favorable)

Ki-67 labeling index (<5% – favorable)

Chromosomes 1p/19q co-deletion (presence – favorable)

MGMT methylation (presence – favorable)

IDH1 mutation (presence – favorable in anaplastic oligodendroglioma)

Proneural gene expression profile (presence – favorable)

Anaplastic neoplasms with homozygous CDKN2A deletion (absence – favorable)

While oligodendrogliomas share the IDH1 mutation in common with astrocytomas, oligodendroglial tumors have distinctive chromosomal losses that correlate with prognosis. These losses were the first example of an association between biologic heterogeneity and genetic profile in a histologically uniform class of CNS neoplasm.

MICROSCOPIC APPEARANCES

Oligodendrogliomas are composed of uniform cells (Figs 36.236.5). These readily infiltrate gray matter, but tend to produce a more abrupt edge in white matter (Fig. 36.2). A lobular architecture is sometimes seen and microcysts can be prominent, particularly in myxoid tumors. Small foci of dystrophic calcification are usually found, often at the edge of the neoplasm or in infiltrated gray matter. A delicate vasculature consisting of branching capillaries runs through typical oligodendrogliomas.

image GENETIC ASPECTS OF GLIOMAS WITH OLIGODENDROGLIAL FEATURES

image A white matter oligodendrocyte progenitor cell has been implicated as the cell of origin for oligodendroglioma.

image Isocitrate dehydrogenase 1 (IDH1) mutation is a common and early genetic event in oligodendroglial tumors (Fig. 36.6). This finding is shared with other low- or intermediate-grade astrocytic and oligoastrocytic neoplasms as well as secondary glioblastomas.

image Allelic loss on chromosome 1p and chromosome 19q is present in as many as 80% of both oligodendrogliomas and anaplastic oligodendrogliomas and is considered an early neoplastic event (Fig. 36.7). Combined 1p/19q loss is not specific for oligodendrogliomas, occurring in oligoastrocytomas. In contrast to IDH1 mutation, 1p/19q loss is rare in astrocytomas.

image In many cases, combined loss of chromosomes 1p and 19q is mediated by an unbalanced translocation, t(1;19)(q10;p10).

image 1p/19q loss is common in frontal, parietal, and occipital oligodendroglial tumors, but infrequent in temporal lobe tumors. Pediatric oligodendrogliomas hardly ever show 1p/19q co-deletion, and then only in tumors from adolescents.

image In oligodendroglial tumors, IDH1 mutation, MGMT methylation, and 1p/19q loss are strongly associated with each other and with a good prognosis.

image A proneural gene expression profile (expression of genes found in normal brain and in neurogenesis) in oligodendroglial tumors is also linked with 1p/19q co-deletion and with improved outcome.

image Several studies indicate an association between response to alkylating chemotherapy or to radiotherapy and co-deletion of chromosomes 1p and 19q in anaplastic oligodendrogliomas. There is consensus that 1p/19q loss is an outcome indicator, but whether this marker is specifically predictive of therapeutic response has recently been questioned.

image Allelic loss on chromosome 17p and TP53 mutation are uncommon in oligodendrogliomas, but TP53 mutation occurs in up to 20% of anaplastic oligodendrogliomas.

image Anaplastic progression of oligodendrogliomas is associated with supplementary losses on chromosomes 9p and 10.

image Homozygous deletion of CDKN2A (p16) on 9p occurs in up to 40% of anaplastic oligodendrogliomas.

image EGFR overexpression that is not due to gene amplification is frequent in oligodendrogliomas and anaplastic oligodendrogliomas.

image Between 20% and 65% of oligoastrocytomas have the 1p/19q loss profile found in oligodendrogliomas, and an oligodendroglioma phenotype predominates in mixed gliomas with this profile.

image Astrocytic and oligodendroglial components of an oligoastrocytoma show the same genetic profile.

image Allelic loss on 17p/TP53 mutation and 1p/19q loss are inversely associated in oligoastrocytomas.

Cytoplasm is rather sparse and not easily identifiable in some cells. Artefactual clearing of the cytoplasm is common in paraffin-embedded material, particularly when fixation is delayed, and gives a ‘fried-egg’ appearance to the cells (Fig. 36.3a). Nuclei are round and usually contain faintly speckled chromatin. A single small nucleolus may be present. Cells occasionally adopt a slightly elongated form, but nuclei retain their characteristic uniformity. Some cells, termed ‘minigemistocytes’, have eccentrically placed nuclei and eosinophilic cytoplasm that is strongly immunoreactive for GFAP (Fig. 36.3d). This overlap with an astrocytic morphophenotype is not on its own indicative of mixed glioma status, but should prompt a search for anaplastic features. Exceptionally, ‘signet-ring’ cells may be evident. Invasion of the subarachnoid space is common (Fig. 36.4). Immunohistochemistry with antibodies to GFAP generally reveals labeling of only a small proportion of cells (Fig. 36.5). Immunoreactivity for myelin-specific proteins is rare. Mitoses are sparse, except in neoplasms with other anaplastic characteristics such as cytologic pleomorphism, microvascular proliferation, and areas of necrosis (Fig. 36.8).

image DIFFERENTIAL DIAGNOSIS OF OLIGODENDROGLIOMA

Pilocytic astrocytoma/clear cell ependymoma/dysembryoplastic neuroepithelial tumor (DNT)/central neurocytoma/clear cell meningioma

image Neoplastic oligodendrocyte-like cells can occur in these tumors, but if sufficient tissue is provided their characteristic histopathologies should permit a definitive diagnosis.

image A biphasic architecture, an idiosyncratic microvascular proliferation, Rosenthal fibers, and cells with a piloid astrocytic phenotype and nuclear pleomorphism are found in the pilocytic astrocytoma.

image Clear cell ependymomas usually contain pseudorosettes and have ultrastructural features not seen in oligodendrogliomas, such as lumina associated with cilia, microvilli, and complex junctions.

image DNTs and oligodendrogliomas can have the same clinical presentation (prolonged epilepsy), but their radiologic appearances are generally distinct. The DNT may also be recognized by its architecture (nodules/cortical location), the astrocytic phenotype of cells in some nodules, and an association with cortical dysplasia. The DNT does not exhibit leptomeningeal spread or satellitosis.

image Neurocytomas are immunoreactive for synaptophysin, and evince neuronal ultrastructural features.

image Clear cell meningiomas are distinguished by their anatomic location, their fibroblastic elements and immunoreactivity for EMA.

EPENDYMOMAS

Gliomas derived from oncogenetic events in cells that manifest ependymal differentiation are divided by the WHO classification into:

The first of these (classic ependymoma) generally presents as an intracranial neoplasm in childhood. The myxopapillary ependymoma, which has a more indolent behavior than the classic ependymoma, nearly always presents as a spinal neoplasm in adulthood. The prognostic significance of anaplasia in ependymomas is not well established. Many studies analyzing the prognostic significance of histopathologic variables have shown no more than a trend towards a poorer outcome for tumors with anaplastic features. Subependymomas are often incidental necropsy findings.

MACROSCOPIC APPEARANCES

Classic ependymomas grow as circumscribed soft gray masses that are generally related to the ventricular system. They are commonest in the posterior fossa, where they may fill the fourth ventricle and pass through its exit foramina (Fig. 36.9).

Myxopapillary ependymomas generally appear as well-defined, lozenge-shaped neoplasms among the cauda equina, which they can sometimes envelop (Fig. 36.10). This behavior can hinder a complete surgical removal. Sectioning reveals tissue with a mucoid texture. Spontaneous hemorrhage into these neoplasms is quite common.

Subependymomas are firm lobulated intraventricular masses and are found predominantly in the fourth ventricle (Fig. 36.11).

MICROSCOPIC APPEARANCES

Ependymomas are generally composed of sheets of uniform cells with indistinct cytoplasmic borders and round or oval nuclei (Fig. 36.12). They are not diffuse gliomas; infiltration of adjacent tissues is minimal, except in some anaplastic examples. The nuclear:cytoplasmic ratio varies; cell density may be high, but infrequent nodules of densely packed cells may be scattered throughout paucicellular areas (Fig. 36.12c). Cells in these nodules may show more nuclear pleomorphism than surrounding cells, and an increased mitotic count. Mitoses should be infrequent and microvascular proliferation absent in classic ependymomas. Foci of micronecrosis without nuclear palisading may be found in classic ependymomas.

Ependymomas label variably with antibodies to GFAP (Fig. 36.13). Focal immunoreactivity for epithelial membrane antigen is sometimes seen around canals. Ultrastructural examination reveals microvilli and cilia on the luminal surfaces, and zonulae adherentes.

The pseudorosette is a perivascular anuclear zone of fibrillary processes that taper towards the vessel (Fig. 36.14). Pseudorosettes are a frequent, though not entirely specific, finding in ependymomas. Ependymal (true) rosettes with a central lumen and a halo of neoplastic cells are more specific, but found less consistently (Fig. 36.14). Rosettes and gland-like canals are a manifestation of epithelial differentiation in ependymomas.

Cellular ependymomas contain cells with a high nuclear: cytoplasmic ratio (Fig. 36.15). Few pseudorosettes are present, and cellular ependymomas do not contain paucicellular areas. Differentiating this variant from an anaplastic ependymoma is difficult, and depends on the identification of an increased mitotic count and cytologic pleomorphism in the latter. Microvascular proliferation and abundant necrosis are also features of most anaplastic ependymomas.

Rarely, intraventricular ependymomas exhibit a papillary pattern, and choroid plexus papilloma (CPP) then enters the differential diagnosis (Fig. 36.16). Papillary ependymomas do not have a subepithelial basement membrane over a fibrovascular core like the CPP, while the CPP does not contain pseudorosettes with tapering GFAP-positive processes.

Clear cell ependymoma may be confused with an oligodendroglioma, but the presence of pseudorosettes should declare its identity (Fig. 36.17). Some ependymomas are composed largely of elongated cells with an astrocytic morphology and have been referred to as tanycytic ependymomas (Fig. 36.18).

Criteria for the diagnosis of anaplastic ependymoma are rather subjective. Necrosis and capillary endothelial proliferation may be widespread in anaplastic ependymomas (Fig. 36.19). The WHO classification emphasizes atypical cytologic features (i.e. nuclear pleomorphism), a high cell density, and plentiful mitoses in its diagnosis. It is important to note that no histologic feature of ependymomas correlates reliably with prognosis.

Myxopapillary ependymomas are characterized by abundant mucin, which envelops and separates clusters and fronds of tumor cells (Fig. 36.20). These tumors usually have monomorphic round nuclei, and may show either epithelioid or glial differentiation. Regions of glial differentiation contain cells with elongated fibrillary processes. Cells with an epithelioid morphophenotype usually form papillary structures with a vascular core. Evidence of previous hemorrhage may be found in the form of hemosiderin-laden macrophages. Intratumoral blood vessels tend to have thick hyalinized walls. Mitoses and foci of necrosis are rare.

Subependymomas are composed of cells with uniform, round or oval nuclei and generally scanty perinuclear cytoplasm. The cells are clustered in small, scattered groups and separated by broad bands of closely packed fibrillary processes. Occasional cells have more abundant, homogeneous, perinuclear cytoplasm. Microcysts are a common finding (Fig. 36.21). Mitoses are absent.

MIXED GLIOMAS

By definition, mixed gliomas are composed of neoplastic cells that show divergent forms of glial differentiation. However, diagnostic criteria for these neoplasms are not well defined, partly because of a degree of histopathologic convergence shown by gliomas. For example, astrocytomas may contain a few cells with an oligodendroglial morphophenotype, and vice versa. Also, clear cell ependymomas contain regions that look oligodendroglial, but clinicopathologic features that tend to separate ependymomas from more diffusely infiltrating gliomas, such as a relatively defined border and a predilection for certain sites, divert the pathologist from a diagnosis of oligoependymoma. This may explain why the terms mixed glioma and oligoastrocytoma are used interchangeably, and why the designations ependymoastrocytoma and oligoependymoma has become obsolete. Given the genetic similarities to astrocytic tumors in some cases and to oligodendrogliomas in others, consideration has been given to dispensing with the oligoastrocytoma category and utilizing molecular stratification to place tumors into astrocytic or oligodendroglial categories. The best approach remains to be determined.

image DIFFERENTIAL DIAGNOSIS OF EPENDYMOMA

MACROSCOPIC AND MICROSCOPIC APPEARANCES

Oligoastrocytoma and anaplastic oligoastrocytoma

Classifications have invoked the diagnosis of oligoastrocytoma in two circumstances (Fig. 36.22): when a glioma consists of two regionally and cytologically distinct populations of cells, one with a clear astrocytic morphophenotype, and the other with features of an oligodendroglioma, and when a glioma consists of cells that exhibit cytologic features that appear to combine astrocytic and oligodendroglial phenotypes. The latter is uncommon. Oligoastrocytomas may contain a small number of mitoses, but if clinical progression is associated with increased cytologic pleomorphism, frequent mitoses, and microvascular proliferation, the term anaplastic oligoastrocytoma is appropriate (Table 36.2). When a tumor has features of an anaplastic oligoastrocytoma but also contains necrosis, the current WHO grading scheme considers such neoplasms as glioblastoma with an oligodendroglial component. The prognosis of these high-grade mixed gliomas with necrosis (glioblastoma with oligodendroglial component) is worse than that of anaplastic mixed gliomas without necrosis, but superior to that of the typical glioblastoma.

REFERENCES

Oligodendrogliomas

Aldape, K., Burger, P.C., Perry, A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med.. 2007;131:242–251.

Ducray, F., Idbaih, A., de Reyniès, A., et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer.. 2008;7:41.

Giannini, C., Burger, P.C., Berkey, B.A., et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol.. 2008;18:360–369.

Griffin, C.A., Burger, P., Morsberger, L., et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol.. 2006;65:988–994.

Godfraind, C., Kaczmarska, J.M., Kocak, M., et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta neuropathologica.. 2012;124:247–257.

Jenkins, R.B., Blair, H., Ballman, K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res.. 2006;66:9852–9861.

Persson, A.I., Petritsch, C., Swartling, F.J., et al. Non-stem cell origin for oligodendroglioma. Cancer Cell.. 2010;18:669–682.

Raghavan, R., Balani, J., Perry, A., et al. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol.. 2003;62:530–537.

van den Bent, M.J., Dubbink, H.J., Sanson, M., et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol.. 2009;27:5881–5886.

Watanabe, T., Nobusawa, S., Kleihues, P., et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol.. 2009;174:1149–1153.

Weller, M., Berger, H., Hartmann, C., et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res.. 2007;13:6933–6937.

Ependymomas

Hegi, M.E., Janzer, R.C., Lambiv, W.L., et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta neuropathologica.. 2012;123:841–852.

Johnson, R.A., Wright, K.D., Poppleton, H., et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature.. 2010;466:632–636.

Korshunov, A., Witt, H., Hielscher, T., et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol.. 2010;28:3182–3190.

Mack, S.C., Taylor, M.D. The genetic and epigenetic basis of ependymoma. Childs Nerv Syst.. 2009;25:1195–1201.

Metellus, P., Guyotat, J., Chinot, O., et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro-oncol.. 2010;12:976–984.

Zacharoulis, S., Moreno, L. Ependymoma: an update. J Child Neurol.. 2009;24:1431–1438.

Share this: